Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION: durvalumab plus olaparib versus durvalumab maintenance in stage IV non-small cell lung cancer
2018-003460-30Phase 2Unknown
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab plus olaparib maintenance with Durvalumab monotherapy maintenance (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
durvalumabolaparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-003460-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003460-30.